Details of the Drug

General Information of Drug (ID: DMK6QBZ)

Drug Name
OMS721
Indication
Disease Entry ICD 11 Status REF
Atypical hemolytic uremic syndrome 3A10.Y Phase 3 [1]
Glomerulonephritis 5D00.Y Phase 2 [2]
Lupus 4A40 Phase 2 [2]
Thrombotic microangiopathy 3B65 Phase 2 [3]
Cross-matching ID
TTD ID
D0QU0H
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mannan-binding lectin serine protease-2 (MASP2) TTR01E9 MASP2_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03205995) Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome (aHUS). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)